New rabies vaccine could cut shots from three visits to one

NCT ID NCT07168018

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new experimental rabies vaccine (ChAdOx2 RabG) given together with the standard rabies vaccine in healthy adults aged 18-45. The goal is to see if this combination is safe and produces a strong immune response, potentially allowing a single visit instead of the usual three. Forty participants in a rabies-endemic country will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ChAdOx2 RabG (experimental rabies vaccine) and inactivated rabies vaccine (Verorab)
What this could lead to
If successful, this could lead to a simpler, single-visit rabies vaccination schedule, improving access in endemic areas.
What could go wrong
This is an early phase II trial with only 40 participants, so results may not apply broadly. Safety and immune response are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RABIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ifakara Health Institute

    Bagamoyo, Tanzania

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.